Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
THYROLAR-0.25 (LIOTRIX (T4;T3)) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
THYROLAR-0.25
NDA
Get alerts
LIOTRIX (T4;T3) | N016807 | ALLERGAN SALES LLC
6 strengths
0 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (6)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 0.0125MG;0.0031MG
RLD
0 patents
0 exclusivities
▴
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982
No patent or exclusivity listings for this strength.
#005 — 0.025MG;0.0063MG
RLD
0 patents
0 exclusivities
▾
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982
#004 — 0.05MG;0.0125MG
RLD
0 patents
0 exclusivities
▾
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982
#002 — 0.1MG;0.025MG
RLD
0 patents
0 exclusivities
▾
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982
#003 — 0.15MG;0.0375MG
RLD
0 patents
0 exclusivities
▾
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982
#006 — 0.25MG;0.0625MG
0 patents
0 exclusivities
▾
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982